Economic Evaluation of Fulvestrant as an Extra Step in the Treatment Sequence for ER-positive Advanced Breast Cancer

British Journal of Cancer - United Kingdom
doi 10.1038/sj.bjc.6604790
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Moesin Is an Independent Prognostic Marker for ER‑positive Breast Cancer

Oncology Letters
Cancer ResearchOncology
2018English

Pcn171 - A Cost-Utility Analysis of Fulvestrant Versus Anastrozole as First-Line Therapy for Oestrogen Receptor-Positive Locally Advanced and Metastatic Breast Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost Effectiveness of Fulvestrant 500 Mg in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer in the UK

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Fulvestrant Treatment Is Associated With Cholesterol Plasma Level Reduction in Hormone Receptor-Positive Metastatic Breast Cancer Patients

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2009English

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde
GynecologyMidwiferyMaternityObstetrics
2019English

Evaluating an ER Degrader for Breast Cancer

Cancer Discovery
Oncology
2015English

Genetically Engineered ER -Positive Breast Cancer Mouse Models

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2014English

A Comparison of Fulvestrant Plus a Targeted Agent With Fulvestrant Alone in Hormone Receptor-Positive Advanced Breast Cancer That Progressed on Prior Endocrine Therapy: A Meta-Analysis

OncoTargets and Therapy
OncologyPharmacology
2018English

Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer

Breast Care
SurgeryOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy